胆固醇和预防心血管事件
Lars G Hemkens1, Hannah Ewald1, Matthias Briel2
1Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.
JAMA
|September 14, 2016
概括
持续的长期素治疗可能会降低心肌梗塞的风险,但会增加胃肠道不良反应. 这一发现对于了解素至关重要.
科学领域:
- 心脏病学
- 药理学
- 临床医学
背景情况:
- 这是一种抗炎药物.
- 目前正在研究长期使用胆固醇对心血管的益处.
- 了解它的安全性是必不可少的.
研究的目的:
- 评估持续的长期素治疗与全因死亡率之间的关联.
- 评估长期使用胆固醇对心肌梗塞发生率的影响.
- 为了确定与长时间的素治疗相关的不良事件的发生率.
主要方法:
- 观察性研究设计.
- 对患者治疗时间的分析.
- 治疗组之间的死亡率和心肌梗塞率的比较.
- 对不良事件报告的评估.
主要成果:
- 持续的长期素治疗可能与心肌梗塞发生率的降低有关.
- 在长期使用素时,观察到胃肠道不良事件的风险增加.
- 这种与全因死亡率的关联需要进一步调查.
结论:
- 长期治疗可提供心血管保护,特别是减少心肌梗塞.
- 临床医生应监测和管理长期使用素的患者的胃肠道副作用.
- 风险与益处的评估对于个体患者的治疗至关重要.
相关概念视频
Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Coronary Artery Disease IV: Preventive Measures
794
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
794
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Coronary Artery Disease V: Interprofessional Care
359
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
359
Atherosclerosis III: Management
558
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Peripheral Artery Disease III: Interprofessional Care
494
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
494

